Xeris Biopharma Holdings Inc (NASDAQ: XERS) stock jumped 2.82% on Monday to $1.82 against a previous-day closing price of $1.77. With 1.88 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.08 million shares. The 52-week range on XERS shows that it touched its highest point at $3.07 and its lowest point at $0.97 during that stretch. It currently has a 1-year price target of $4.60. Beta for the stock currently stands at 1.43.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XERS was up-trending over the past week, with a rise of 12.35%, but this was up by 4.60% over a month. Three-month performance dropped to -20.52% while six-month performance fell -38.31%. The stock gained 43.31% in the past year, while it has gained 36.84% so far this year. A look at the trailing 12-month EPS for XERS yields -0.45 with Next year EPS estimates of -0.25. For the next quarter, that number is -0.09. This implies an EPS growth rate of 44.00% for this year and 37.34% for next year.
Float and Shares Shorts:
At present, 136.27 million XERS shares are outstanding with a float of 129.56 million shares on hand for trading. On Oct 30, 2023, short shares totaled 7.79 million, which was 5.65% higher than short shares on Sep 28, 2023. In addition to Mr. Paul R. Edick as the firm’s Chairman & CEO, Mr. John P. Shannon serves as its President & COO.
Through their ownership of 38.29% of XERS’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 4.54% of XERS, in contrast to 22.09% held by mutual funds. Shares owned by individuals account for 17.22%. As the largest shareholder in XERS with 6.09% of the stake, BlackRock Fund Advisors holds 8,401,872 shares worth 8,401,872. A second-largest stockholder of XERS, The Vanguard Group, Inc., holds 6,759,197 shares, controlling over 4.90% of the firm’s shares. Stonepine Capital Management LLC is the third largest shareholder in XERS, holding 5,915,372 shares or 4.28% stake. With a 2.98% stake in XERS, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 4,106,991 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 2.24% of XERS stock, is the second-largest Mutual Fund holder. It holds 3,093,962 shares valued at 5.66 million. Xtrackers SICAV – S&P Global Infr holds 1.45% of the stake in XERS, owning 1,999,189 shares worth 3.66 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XERS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With XERS analysts setting a high price target of $5.50 and a low target of $4.00, the average target price over the next 12 months is $4.60. Based on these targets, XERS could surge 202.2% to reach the target high and rise by 119.78% to reach the target low. Reaching the average price target will result in a growth of 152.75% from current levels.
Summary of Insider Activity:
Insiders traded XERS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 16 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 3,262,500 while 0 shares were sold.